TRCT
VBIO

Tower Research Capital (TRC)’s Valion Bio VBIO Stock Holding History

Tower Research Capital (TRC)’s Portfolio VBIO Stock Details VBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.09K Buy
84
+61
+265% +$1.33K ﹤0.01% 4892
2026
Q1 		$517 Sell
23
-43
-65% -$1.1K ﹤0.01% 4851
2025
Q4 		$2.39K Buy
+66
New +$3.76K ﹤0.01% 4541
2025
Q1 		– Sell
-44
Closed -$6.53K – 5781
2024
Q4 		$6.53K Buy
44
+1
+2% +$116 ﹤0.01% 4162
2024
Q3 		$4.59K Buy
43
+26
+153% +$3.92K ﹤0.01% 4487
2024
Q2 		$2.84K Buy
17
+3
+21% +$944 ﹤0.01% 4960
2024
Q1 		$7.7K Buy
14
+8
+133% +$4.62K ﹤0.01% 4162
2023
Q4 		$4.24K Buy
6
+5
+500% +$3.59K ﹤0.01% 4978
2023
Q3 		$1.06K Buy
+1
New +$1.85K ﹤0.01% 5414
2023
Q2 		– Hold
0
– – – 5443
2023
Q1 		– Hold
0
– – – 5404
2022
Q4 		– Hold
0
– – – 4623
2022
Q3 		– Hold
0
– – – 4467
2022
Q2 		– Hold
0
– – – 4486
2022
Q1 		– Hold
0
– – – 5102

Other funds holding VBIO

M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
MG
Marex Group London $23.6B AUM 57.16% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Tower Research Capital (TRC)'s VBIO Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Valion Bio (VBIO) stake by 265% in Q2 2026, buying an estimated $1.33K and bringing the position to 84 shares worth $1.09K. The position accounts for ﹤0.01% of the portfolio, ranked #4892.

Tower Research Capital (TRC) first reported a position in VBIO in Q3 2023 and has held it in 9 quarters since. The position peaked at $7.7K in Q1 2024. 11 funds tracked by Wall St. Rank hold VBIO as of Q2 2026.

  • Tower Research Capital (TRC) held 84 shares of Valion Bio worth $1.09K as of Q2 2026.
  • Tower Research Capital (TRC) bought 61 Valion Bio shares in Q2 2026, an estimated $1.33K.
  • Valion Bio made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4892 holding.
  • Tower Research Capital (TRC) first reported a position in Valion Bio in Q3 2023 and has held it in 9 quarters since.
  • Tower Research Capital (TRC)'s Valion Bio position peaked at $7.7K in Q1 2024.
  • 11 funds tracked by Wall St. Rank held Valion Bio as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.